Skip to main content
Premium Trial:

Request an Annual Quote

Andre Hoekema, Metin Colpan, Craig Mello, Douglas Coleman, Jeffrey Friedman, Brenda Milner, Endel Tulving, Michael Catelani, Sara Cunningham

Premium

Galapagos Genomics said this week that it has appointed Andre Hoekema as managing director of Galadeno, the company's viral-based discovery and validation business unit.

Hoekema joins Galadeno from Invitrogen, where he was managing director of corporate development Europe. He has also held positions at Molecular Probes Europe, Crucell, DSM Life Sciences, and Genentech.

He holds a PhD in physics and mathematics from Leiden University.


Metin Colpan this week was appointed to the supervisory board of Genpat77, the Berlin-based company said.

Colpan co-founded and was CEO of Qiagen until the end of 2003. He has remained at Qiagen as senior technology advisor and member of its supervisory board. Prior to founding Qiagen, Colpan was an investigator at the Institute for Biophysics at the University of Dusseldorf, Germany.

Colpan sits on the boards of several companies, including GPC Biotech, Morphosys, and Ingenium. He earned his PhD and MS in organic chemistry and chemical engineering from the Darmstadt Institute of Technology, Germany, in 1983.


Craig Mello, RNAi pioneer and chairman of molecular medicine at the University of Massachusetts Medical School, was one of six scientists named as winners of the Gairdner International awards announced this month. Also winning was Andrew Fire, professor of pathology and genetics at Stanford University School of Medicine.

Other winners included: Douglas Coleman, senior staff scientist, emeritus, of the Jackson Lab of Bar Harbor, Maine; Jeffrey Friedman of Rockefeller University of New York and director of the Staff Center for Human Genetics; Brenda Milner, professor of cognitive neuroscience, Montreal Neurological Institute of McGill University in Montreal; and Endel Tulving, chairman of cognitive neuroscience, Rotman Research Institute, University of Toronto.


Benitec said this week that it has appointed Michael Catelani as the company's CFO.

Catelani will oversee Benitec's financial management, accounting, and investor relations, and will report directly to CEO Sara Cunningham.

Catelani has served as a consultant to Benitec since January. Before this, he was a consultant to an undisclosed Australian biotech firm, said Benitec. He has also served as CFO at Axon Instruments, and vice president of finance at Media Arts Group.

Catelani holds an MBA from the University of California, Davis.

The Scan

Gone, But Now Reconstructed SARS-CoV-2 Genomes

In a preprint, a researcher describes his recovery of viral sequences that had been removed from a common database.

Rare Heart Inflammation Warning

The Food and Drug Administration is adding a warning about links between a rare inflammatory heart condition and two SARS-CoV-2 vaccines, Reuters reports.

Sandwich Sampling

The New York Times sent tuna sandwiches for PCR analysis.

Nature Papers Describe Gut Viruses, New Format for Storing Quantitative Genomic Data, More

In Nature this week: catalog of DNA viruses of the human gut microbiome, new dense depth data dump format to store quantitative genomic data, and more.